Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2013. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital disclosure notice rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of January 31, 2013:
- Total Issued Ordinary Shares: 5,398,727,128 (25p each)
- Treasury Shares: 494,951,327
- Total Voting Rights: 4,903,775,801
No comparative data for prior periods is included in this specific text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory capital disclosure.
Investor Verification Checklist
- Verify the total number of voting rights (4,903,775,801) for compliance with disclosure thresholds.
- Confirm the number of shares held in Treasury (494,951,327) to calculate the free float.
- Check subsequent filings for financial performance data, as this 6-K does not contain earnings metrics.